These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 12898184)

  • 21. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
    Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
    Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
    Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
    Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
    J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G; Pöschel V; Pfreundschuh M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
    Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
    Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.
    Vassallo J; Bousquet M; Quelen C; Al Saati T; Delsol G; Brousset P
    J Clin Pathol; 2007 May; 60(5):573-5. PubMed ID: 17513519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-Hodgkin's lymphomas involving the uterus: a clinicopathologic analysis of 26 cases.
    Vang R; Medeiros LJ; Ha CS; Deavers M
    Mod Pathol; 2000 Jan; 13(1):19-28. PubMed ID: 10658906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X; Hu W; Qin X
    Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
    Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
    Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
    Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
    Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
    Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
    J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.